A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data
Fertility and Sterility, ISSN: 0015-0282, Vol: 83, Issue: 3, Page: 804-807
2005
- 13Citations
- 16Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations13
- Citation Indexes13
- CrossRef13
- 13
- Captures16
- Readers16
- 16
Article Description
This study compared the cost and effectiveness of highly purified, human-derived follicle-stimulating hormone (FSH) (Bravelle ® ) to recombinant FSH (Follistim ® ) using Markov modeling and Monte Carlo simulation. One IVF treatment cycle resulted in costs of $11,584 ± $211 for human-derived FSH and $12,762 ± $170 for recombinant FSH, while three treatment cycles, holding the transition probabilities of the first cycle constant for the next two cycles, resulted in costs of $22,712 ± $1,107 for human-derived FSH and $24,935 ± $1,205 for recombinant FSH.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0015028204030146; http://dx.doi.org/10.1016/j.fertnstert.2004.08.024; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=14844300128&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/15749525; https://linkinghub.elsevier.com/retrieve/pii/S0015028204030146; https://dx.doi.org/10.1016/j.fertnstert.2004.08.024
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know